Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Work
Year: 2017
Type: article
Abstract: Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment wi... more
Source: New England Journal of Medicine
Institutions George Institute for Global Health, Harry Perkins Institute of Medical Research, UNSW Sydney, Imperial College London, Royal North Shore Hospital +9 more
Cites: 27
Cited by: 6,658
Related to: 10
FWCI: 604.8
Citation percentile (by year/subfield): 99.99
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze